In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
The proportion of risk for alcohol use disorder (AUD) that can be attributed to genetic factors is as high as 60%. This data invokes heritability comparisons to both…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
The Centers for Disease Control and Prevention (CDC) has produced a new video for healthcare providers who treat or dispense medications to women of reproductive age. This short…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
Abbott has developed two types of implantable neurostimulation devices that employ two advanced spinal column stimulation (SCS) techniques, respectively, dorsal root ganglion (DRG) stimulation and Abbott’s proprietary BURSTDR™…
Exoskeletons intended for medical purposes are motorized braces that help control a patient’s body and limb movements. These sophisticated body frames are increasingly being used as a tool…
Deep brain stimulation (DBS) is a widely-used neurological technique for modifying and rehabilitating brain function. Closed-loop or “smart” DBS systems currently under development are the next evolutionary step…
Alcohol use disorder (AUD) is notoriously difficult to treat, but a new therapeutic option may be on the horizon. Ondansetron, a competitive serotonin type 3 receptor antagonist currently…
